OPERATING_VBG ACTIVITIES_NNS MARKETING_VBG AND_CC DISTRIBUTION_NNP Smith_NNP &_CC Nephews_NNP customers_NNS are_VBP the_DT various_JJ providers_NNS of_IN medical_JJ and_CC surgical_JJ services_NNS worldwide_NN ._.
In_IN certain_JJ parts_NNS of_IN the_DT world_NN ,_, including_VBG the_DT UK_NNP ,_, much_RB of_IN Continental_NNP Europe_NNP ,_, Australia_NNP ,_, Canada_NNP and_CC South_NNP Africa_NNP ,_, these_DT are_VBP largely_RB governmental_JJ organizations_NNS funded_VBN by_IN tax_NN revenues_NNS ._.
In_IN the_DT US_NNP ,_, the_DT Groups_NNS major_JJ customers_NNS are_VBP public_JJ and_CC private_JJ hospitals_NNS ,_, many_JJ of_IN which_WDT have_VBP combined_VBN to_TO form_VB large_JJ purchasing_NN groups_NNS and_CC receive_VB revenue_NN from_IN private_JJ health_NN insurance_NN and_CC governmental_JJ reimbursement_NN programs_NNS ._.
In_IN the_DT US_NNP ,_, Medicare_NNP is_VBZ the_DT major_JJ source_NN of_IN reimbursement_NN for_IN knee_NN and_CC and_CC for_IN regimes_NNS ._.
Competition_NN exists_VBZ among_IN healthcare_NN providers_NNS to_TO gain_VB patients_NNS on_IN the_DT basis_NN of_IN quality_NN ,_, service_NN and_CC price_NN ._.
In_IN many_JJ countries_NNS ,_, providers_NNS are_VBP under_IN pressure_NN to_TO reduce_VB the_DT total_JJ cost_NN of_IN healthcare_NN delivery_NN ._.
There_EX has_VBZ been_VBN some_DT consolidation_NN in_IN the_DT Groups_NNS customer_NN base_NN ,_, as_RB well_RB as_IN amongst_IN the_DT Groups_NNS competitors_NNS ,_, and_CC these_DT trends_NNS are_VBP expected_VBN to_TO continue_VB in_IN the_DT long_JJ term_NN ._.
Smith_NNP &_CC Nephew_NNP competes_VBZ against_IN both_DT specialised_VBN and_CC multinational_JJ corporations_NNS ,_, includingthose_JJ withgreater_NN financial_JJ ,_, marketingand_JJ other_JJ resources_NNS ._.
The_DT Groups_NNS customers_NNS reflect_VBP the_DT wide_JJ range_NN of_IN distribution_NN channels_NNS ,_, purchasing_VBG agents_NNS and_CC buying_VBG entities_NNS in_IN over_IN 90_CD countries_NNS worldwide_JJ ._.
The_DT largest_JJS single_JJ customers_NNS worldwide_NN are_VBP the_DT National_NNP Health_NNP Service_NNP in_IN the_DT UK_NNP and_CC HealthTrust_NNP in_IN the_DT US_NNP ._.
Sales_NNS to_TO these_DT customers_NNS in_IN 2005_CD represented_VBD approximately_RB 5_CD %_NN and_CC 4_CD %_NN of_IN the_DT Groups_NNS worldwiderevenue_VBP respectively_RB ._.
In_IN the_DT US_NNP the_DT Groups_NNS products_NNS are_VBP marketed_VBN directly_RB to_TO doctors_NNS ,_, hospitals_NNS and_CC other_JJ healthcare_NN facilities_NNS ._.
Each_DT business_NN unit_NN operates_VBZ a_DT separate_JJ specialised_JJ sales_NNS force_NN ._.
Within_IN the_DT orthopaedics_NNS business_NN further_JJ specialisation_NN of_IN the_DT sales_NNS force_NN continues_VBZ to_TO be_VB introduced_VBN progressively_RB for_IN reconstruction_NN ,_, trauma_NN and_CC clinical_JJ therapy_NN products_NNS ._.
In_IN both_DT orthopaedics_NNS reconstruction_NN and_CC endoscopy_JJ the_DT US_NNP sales_NNS forces_NNS consist_VBP largely_RB of_IN independent_JJ commissioned_VBN sales_NNS agents_NNS who_WP are_VBP managed_VBN by_IN a_DT mix_NN of_IN independent_JJ agents_NNS and_CC the_DT Groups_NNS own_VBP managers_NNS ._.
These_DT agents_NNS are_VBP not_RB permitted_VBN contractually_RB to_TO sell_VB products_NNS that_WDT compete_VBP with_IN Smith_NNP &_CC Nephews_NNP ._.
In_IN both_DT businesses_NNS ,_, products_NNS are_VBP shipped_VBN and_CC invoiced_VBN directly_RB to_TO the_DT ultimate_JJ customer_NN ._.
The_DT trauma_NN and_CC clinical_JJ therapies_NNS and_CC advanced_JJ wound_NN management_NN businesses_NNS in_IN the_DT US_NNP operate_VBP sales_NNS forces_NNS of_IN their_PRP$ own_JJ employees_NNS who_WP market_VBP directly_RB to_TO the_DT ultimate_JJ customer_NN ._.
In_IN the_DT US_NNP ,_, trauma_NN and_CC clinical_JJ therapy_NN products_NNS are_VBP shipped_VBN and_CC invoiced_VBN directly_RB to_TO the_DT ultimate_JJ customer_NN whereas_IN advanced_JJ wound_NN management_NN products_NNS are_VBP shipped_VBN and_CC invoicedto_VB a_DT numberof_JJ large_JJ wholesale_JJ distributors_NNS ._.
In_IN the_DT other_JJ direct_JJ markets_NNS of_IN the_DT UK_NNP ,_, Ireland_NNP ,_, France_NNP ,_, Germany_NNP ,_, Italy_NNP ,_, Australia_NNP ,_, New_NNP Zealand_NNP ,_, Canada_NNP and_CC Japan_NNP the_DT business_NN units_NNS manage_VBP separate_JJ sales_NNS forces_NNS directly_RB ._.
Except_IN in_IN Australia_NNP and_CC New_NNP Zealand_NNP where_WRB independent_JJ sales_NNS agents_NNS are_VBP used_VBN the_DT sales_NNS forces_NNS of_IN the_DT direct_JJ markets_NNS comprise_VBP employees_NNS and_CC market_NN directly_RB to_TO the_DT ultimate_JJ customer_NN ._.
The_DT indirect_JJ markets_NNS unit_NN comprises_VBZ direct_JJ selling_NN and_CC marketingoperations_NNS inAustria_NNP ,_, Belgium_NNP ,_, Denmark_NNP ,_, Eastern_NNP Europe_NNP ,_, Finland_NNP ,_, the_DT Netherlands_NNP ,_, Norway_NNP ,_, Poland_NNP ,_, Portugal_NNP ,_, Spain_NNP ,_, Sweden_NNP ,_, Switzerland_NNP ,_, China_NNP ,_, Hong_NNP Kong_NNP ,_, Korea_NNP ,_, Malaysia_NNP ,_, Singapore_NNP ,_, Taiwan_NNP ,_, Thailand_NNP ,_, the_DT United_NNP Arab_NNP Emirates_NNP ,_, South_NNP Africa_NNP ,_, Mexico_NNP and_CC Puerto_NNP Rico_NNP ._.
In_IN these_DT markets_NNS orthopaedics_NNS and_CC endoscopy_JJ frequently_RB share_NN sales_NNS resources_NNS ._.
The_DT advanced_JJ wound_NN management_NN sales_NNS force_NN is_VBZ separate_JJ since_IN it_PRP calls_VBZ on_IN different_JJ customers_NNS ._.
In_IN all_DT other_JJ countries_NNS Smith_NNP &_CC Nephew_NNP sells_VBZ to_TO third_JJ party_NN distributors_NNS whichmarket_VBP the_DT Groups_NNS products_NNS locally_RB ._.
In_IN Continental_NNP Europe_NNP ,_, the_DT Group_NNP operates_VBZ three_CD centralised_JJ distribution_NN facilities_NNS ._.
Orthopaedics_NNP operates_VBZ a_DT facility_NN in_IN Paris_NNP which_WDT acts_VBZ as_IN a_DT central_JJ holding_NN and_CC consolidation_NN point_NN for_IN Continental_JJ European_JJ stock_NN and_CC stock_NN returns_NNS ._.
Product_NN is_VBZ shipped_VBN to_TO Group_NNP companies_NNS who_WP hold_VBP small_JJ amounts_NNS of_IN stock_NN locally_RB for_IN immediate_JJ or_CC urgent_JJ customer_NN requirements_NNS ._.
Advanced_NNP wound_VBD management_NN operates_VBZ distribution_NN centres_NNS at_IN Nijmegen_NNP ,_, Netherlands_NNP and_CC Gothenburg_NNP ,_, Sweden_NNP from_IN where_WRB stock_NN is_VBZ shipped_VBN directly_RB to_TO the_DT ultimate_JJ customer_NN in_IN most_JJS European_JJ markets_NNS ._.
MANUFACTURE_NNPS AND_CC SUPPLY_NNP Where_WRB management_NN considers_VBZ that_IN the_DT Group_NNP possesses_VBZ a_DT core_NN competence_NN its_PRP$ policy_NN is_VBZ to_TO manufacture_VB products_NNS internally_RB whenever_WRB possible_JJ to_TO ensure_VB quality_NN ,_, regulatory_JJ and_CC cost_NN goals_NNS are_VBP met_VBN ._.
The_DT Group_NNP invests_VBZ in_IN the_DT expansion_NN of_IN its_PRP$ manufacturing_NN facilities_NNS and_CC equipment_NN to_TO meet_VB these_DT aims_NNS ._.
The_DT Group_NNP may_MD outsource_VB some_DT manufacturing_NN for_IN several_JJ reasons_NNS including_VBG requirements_NNS for_IN specialised_JJ expertise_NN ,_, where_WRB appropriate_JJ to_TO achieve_VB lowercosts_NNS of_IN productionand_NN due_JJ to_TO capacity_NN constraints_NNS ._.
13_CD Where_WRB products_NNS and_CC services_NNS are_VBP outsourced_VBN ,_, suppliers_NNS are_VBP determined_VBN based_VBN on_IN a_DT number_NN of_IN factors_NNS which_WDT include_VBP the_DT complexity_NN of_IN the_DT product_NN ,_, manufacturing_VBG technology_NN ,_, manufacturing_VBG capabilities_NNS ,_, cost_NN competitiveness_NN and_CC intellectual_JJ property_NN ._.
Suppliers_NNS are_VBP selected_VBN based_VBN on_IN their_PRP$ capability_NN to_TO provide_VB products_NNS and_CC services_NNS ,_, their_PRP$ ability_NN to_TO establish_VB and_CC maintain_VB a_DT quality_NN system_NN and_CC their_PRP$ financial_JJ stability_NN ._.
Suppliers_NNS are_VBP monitored_VBN by_IN on-site_JJ assessments_NNS and_CC on-going_JJ monitoring_NN of_IN delivered_VBN products_NNS ._.
Ongoing_JJ product_NN assurance_NN is_VBZ maintainedby_JJ effective_JJ quality_NN plans_NNS ._.
Each_DT business_NN unit_NN purchases_NNS raw_JJ materials_NNS ,_, components_NNS ,_, finished_VBD products_NNS and_CC packaging_NN materials_NNS from_IN certain_JJ key_JJ suppliers_NNS ._.
These_DT comprise_VBP principally_RB metal_NN forgings_NNS and_CC stampings_NNS for_IN orthopaedics_NNS ,_, optical_JJ and_CC electronic_JJ sub-components_NNS and_CC finished_VBN goods_NNS for_IN endoscopy_JJ ,_, active_JJ ingredients_NNS and_CC finished_VBN goods_NNS for_IN advanced_JJ wound_NN management_NN and_CC packaging_NN materials_NNS for_IN all_DT businesses_NNS ._.
Management_NNP believes_VBZ that_IN whilst_NN prices_NNS of_IN principal_JJ raw_JJ materials_NNS can_MD be_VB volatile_JJ the_DT effect_NN is_VBZ not_RB material_JJ to_TO the_DT Group_NNP ._.
Finished_VBN goods_NNS purchased_VBD for_IN resale_NN are_VBP primarily_RB SUPARTZ_NNP joint_JJ lubricant_NN and_CC the_DT BHR_NNP hip_NN resurfacing_VBG product_NN in_IN the_DT orthopaedic_JJ business_NN ,_, screen_NN displays_NNS and_CC electrical_JJ devices_NNS in_IN the_DT endoscopy_JJ business_NN and_CC enzyme_NN debrider_NN agents_NNS and_CC ACTICOAT_NNP in_IN the_DT advanced_JJ woundmanagement_NN business_NN ._.
SEASONALITY_NNP Smith_NNP &_CC Nephews_NNP revenues_NNS are_VBP generally_RB at_IN their_PRP$ highest_JJS in_IN quarter_NN four_CD of_IN any_DT year_NN ._.
This_DT is_VBZ caused_VBN by_IN the_DT relatively_RB high_JJ number_NN of_IN accidents_NNS and_CC sports_NNS injuries_NNS which_WDT occur_VBP in_IN the_DT North_JJ American_JJ and_CC European_JJ autumn_NN and_CC winter_NN seasons_NNS which_WDT increase_VBP revenues_NNS of_IN orthopaedic_JJ and_CC endoscopy_JJ products_NNS and_CC by_IN the_DT higher_JJR rates_NNS of_IN elective_JJ surgery_NN inthe_JJ quarter_NN ._.
RESEARCH_NN AND_CC DEVELOPMENT_NNP The_DT business_NN units_NNS each_DT manage_VBP a_DT portfolio_NN of_IN short_JJ and_CC long-term_JJ product_NN development_NN projects_NNS designed_VBN to_TO meet_VB the_DT future_JJ needs_NNS of_IN their_PRP$ customers_NNS and_CC to_TO continue_VB to_TO provide_VB growth_NN opportunities_NNS for_IN their_PRP$ businesses_NNS ._.
The_DT Groups_NNS research_NN and_CC development_NN is_VBZ directed_VBN towards_IN all_DT three_CD business_NN segments_NNS ._.
Expenditure_NN on_IN research_NN and_CC development_NN amounted_VBD to_TO 67m_VB in_IN 2005_CD 2004_CD 66m_NN ,_, 2003_CD 67m_CD ,_, representing_VBG approximately_RB 5_CD %_NN of_IN groupturnover_NN 2004_CD 5_CD %_NN ,_, 2003_CD 6_CD %_NN ._.
The_DT Groups_NNS principal_JJ research_NN facility_NN is_VBZ located_VBN in_IN York_NNP ,_, England_NNP ._.
The_DT Groups_NNS research_NN program_NN seeks_VBZ to_TO underpin_VB the_DT longer-term_JJ technology_NN requirements_NNS for_IN its_PRP$ businesses_NNS and_CC to_TO provide_VB a_DT flow_NN of_IN innovative_JJ products_NNS ._.
The_DT Group_NNP continues_VBZ to_TO invest_VB in_IN future_JJ technology_NN opportunities_NNS ,_, particularly_RB bio-resorbable_JJ materials_NNS ,_, tissue_NN engineering_NN and_CC non-invasive_JJ healing_NN devices_NNS across_IN the_DT Group_NNP ._.
In-house_JJ research_NN is_VBZ supplemented_VBN by_IN work_NN ._.
Product_NN development_NN is_VBZ carried_VBN out_RP at_IN the_DT Groups_NNS principal_JJ locations_NNS ,_, notably_RB in_IN Memphis_NNP ,_, Tennessee_NNP orthopaedics_NNS ,_, Andover_NNP and_CC Mansfield_NNP ,_, Massachusetts_NNP endoscopy_JJ and_CC Hull_NNP ,_, England_NNP advanced_VBD wound_NN management_NN ._.
INTELLECTUAL_JJ PROPERTY_NN Management_NN believes_VBZ that_IN the_DT Groups_NNS policy_NN concerning_VBG intellectual_JJ property_NN rights_NNS promotes_VBZ innovation_NN in_IN its_PRP$ businesses_NNS ._.
Smith_NNP &_CC Nephew_NNP has_VBZ a_DT policy_NN of_IN protecting_VBG ,_, with_IN patents_NNS ,_, the_DT results_NNS of_IN the_DT research_NN and_CC development_NN carried_VBD out_RP by_IN the_DT Group_NNP ._.
Patents_NNP have_VBP been_VBN obtained_VBN for_IN a_DT wide_JJ range_NN of_IN products_NNS ,_, including_VBG those_DT in_IN the_DT fields_NNS of_IN orthopaedic_JJ ,_, endoscopic_JJ and_CC advanced_JJ wound_NN management_NN technologies_NNS ._.
Patent_NN protection_NN for_IN Group_NNP products_NNS is_VBZ sought_VBN routinely_RB in_IN the_DT Groups_NNS principal_JJ markets_NNS ._.
Currently_RB ,_, the_DT Groups_NNS patent_NN portfolio_NN stands_VBZ at_IN over_IN 2,300_CD existing_VBG patents_NNS and_CC patent_NN applications_NNS ._.
Smith_NNP &_CC Nephew_NNP also_RB has_VBZ a_DT policy_NN of_IN protecting_VBG the_DT Groups_NNS products_NNS in_IN the_DT markets_NNS in_IN which_WDT they_PRP are_VBP sold_VBN by_IN registering_VBG trademarks_NNS as_RB soon_RB as_IN possible_JJ under_IN local_JJ laws_NNS ._.
The_DT Group_NNP vigorously_RB protects_VBZ its_PRP$ trademarks_NNS against_IN infringement_NN and_CC currently_RB is_VBZ not_RB aware_JJ of_IN any_DT significant_JJ infringement_NN of_IN its_PRP$ trademark_NN registrations_NNS ._.
The_DT present_JJ trademark_NN portfolioof_NN the_DT Group_NNP consists_VBZ of_IN over_IN 3,300_CD trademarks_NNS and_CC design_NN rights_NNS ._.
Smith_NNP &_CC Nephews_NNP principal_JJ products_NNS are_VBP protected_VBN by_IN intellectual_JJ property_NN comprising_VBG patents_NNS ,_, licences_NNS and_CC know-how_NN ,_, and_CC it_PRP strives_VBZ to_TO provide_VB a_DT collection_NN of_IN intellectual_JJ property_NN for_IN each_DT major_JJ product_NN that_WDT reduces_VBZ the_DT risk_NN associated_VBN with_IN failure_NN of_IN any_DT individual_JJ piece_NN of_IN intellectual_JJ property_NN ._.
In_IN addition_NN ,_, most_JJS pieces_NNS of_IN intellectual_JJ property_NN protect_VBP a_DT relatively_RB small_JJ proportion_NN of_IN the_DT Groups_NNS annual_JJ revenue_NN ._.
As_IN a_DT result_NN ,_, the_DT Group_NNP tries_VBZ to_TO ensure_VB that_IN its_PRP$ overall_JJ business_NN is_VBZ not_RB sensitive_JJ to_TO the_DT loss_NN however_RB caused_VBD of_IN any_DT single_JJ piece_NN of_IN intellectual_JJ property_NN ._.
14_CD In_IN addition_NN to_TO maintaining_VBG a_DT policy_NN of_IN protecting_VBG its_PRP$ market_NN position_NN by_IN the_DT filing_NN and_CC enforcement_NN of_IN patents_NNS and_CC trademarks_NNS ,_, Smith_NNP &_CC Nephew_NNP has_VBZ a_DT policy_NN of_IN opposing_VBG third_JJ party_NN patents_NNS and_CC trademarks_NNS in_IN those_DT areas_NNS that_WDT mightconflictwiththe_VBP Groups_NNS business_NN interests_NNS ._.
In_IN the_DT ordinary_JJ course_NN of_IN its_PRP$ business_NN ,_, the_DT Group_NNP enters_VBZ into_IN a_DT number_NN of_IN licensing_NN arrangements_NNS with_IN respect_NN to_TO its_PRP$ products_NNS ._.
None_NN of_IN these_DT arrangements_NNS individually_RB is_VBZ considered_VBN material_NN to_TO the_DT operations_NNS and_CC the_DT financial_JJ results_NNS of_IN the_DT Group_NNP ._.
PROPERTY_NN ,_, PLANT_NNP AND_CC EQUIPMENT_NNP TheGroups_NNS as_IN follows_VBZ :_: Approximate_JJ area_NN Square_NNP feet_NNS 000s_CD Group_NNP Head_NNP Office_NNP inLondon_NNP ,_, England_NNP ..._: ..._: ..._: ..._: ..._: ..._: ..._: ..._: ..._: ..._: 15_CD Group_NNP research_NN facility_NN inYork_NNP ,_, England_NNP ..._: ..._: ..._: ..._: ..._: ..._: ..._: ..._: ..._: ..._: 83_CD Orthopaedics_NNPS headquarters_NN and_CC inMemphis_NNP ,_, Tennessee_NNP ..._: ..._: ..._: 784_CD Orthopaedics_NNPS distributionfacility_NN inMemphis_NNP ,_, Tennessee_NNP ..._: ..._: ..._: ..._: ..._: ..._: ..._: 102_CD Orthopaedics_NNPS inMemphis_NNP ,_, Tennessee_NNP ..._: ..._: ..._: ..._: ..._: ..._: ._.
84_CD inAndover_NNP ,_, Massachusetts_NNP ..._: ..._: ..._: ..._: ..._: ..._: ..._: ._. ._.
112_CD inMansfield_NNP ,_, Massachusetts_NNP ..._: ..._: ..._: ..._: ..._: ..._: 98_CD inOklahomaCity_NN ,_, Oklahoma_NNP ..._: ..._: ..._: ..._: ..._: ..._: 100_CD Advanced_NNP WoundManagement_NNP headquarters_NN and_CC inHull_NNP ,_, England_NNP ..._: ..._: 546_CD Advanced_NNP WoundManagement_NNP inGilberdyke_NNP ,_, England_NNP ..._: ..._: ..._: ._. ._.
269_CD Advanced_NNP WoundManagement_NNP inLargo_NNP ,_, Florida_NNP ..._: ..._: ..._: ..._: ..._: 188_CD The_DT orthopaedic_JJ headquarters_NN and_CC manufacturing_NN facilities_NNS in_IN Memphis_NNP and_CC the_DT advanced_JJ wound_NN management_NN facilities_NNS in_IN Hull_NNP ,_, Gilberdyke_NNP and_CC Largo_NNP are_VBP freehold_VBN while_IN all_DT other_JJ leasehold_NN ._.
TheGroup_NNP has_VBZ freehold_VBN and_CC leasehold_VBN interests_NNS in_IN real_JJ estate_NN in_IN other_JJ countries_NNS throughout_IN the_DT world_NN ,_, but_CC no_DT other_JJ is_VBZ significant_JJ individuallyto_NN the_DT Group_NNP ._.
Whererequired_NNP ,_, the_DT appropriate_JJ governmental_JJ authoritieshave_NN approved_VBD the_DT facilities_NNS ._.
During_IN 2005_CD the_DT Group_NNP announced_VBD the_DT closure_NN of_IN two_CD of_IN its_PRP$ manufacturing_NN locations_NNS ._.
The_DT endoscopy_JJ facility_NN in_IN Andover_NNP ,_, Massachusetts_NNP will_MD be_VB closed_VBN gradually_RB during_IN 2006_CD and_CC its_PRP$ production_NN relocated_VBD partly_RB to_TO other_JJ endoscopy_JJ facilities_NNS and_CC partly_RB out-sourced_JJ to_TO third_JJ party_NN suppliers_NNS ._.
Production_NN at_IN the_DT advanced_JJ wound_NN management_NN facility_NN in_IN La_NNP Jolla_NNP ,_, California_NNP has_VBZ ceased_VBN following_VBG the_DT decision_NN to_TO exit_NN its_PRP$ tissue_NN engineering_NN operations_NNS and_CC the_DT facility_NN willbe_NN closed_VBD inthe_NN first_JJ quarter_NN of_IN 2006_CD ._.
As_IN a_DT result_NN of_IN its_PRP$ rapid_JJ rate_NN of_IN sales_NNS growth_NN in_IN recent_JJ years_NNS and_CC anticipated_VBN continuing_VBG strong_JJ demand_NN for_IN its_PRP$ products_NNS ,_, the_DT orthopaedics_NNS business_NN increased_VBD its_PRP$ manufacturing_NN capacity_NN and_CC administrative_JJ facilities_NNS in_IN 2005_CD in_IN line_NN with_IN its_PRP$ capacity_NN expansion_NN plans_NNS ._.
Additional_JJ freehold_NN manufacturing_VBG space_NN of_IN 104,000_CD square_JJ feet_NNS and_CC leasehold_NN administrative_JJ space_NN of_IN 84,000_CD square_JJ feet_NNS were_VBD acquiredinMemphis_NNP ._.
During_IN 2005_CD ,_, in_IN the_DT UK_NNP ,_, new_JJ leasehold_NN facilities_NNS for_IN the_DT development_NN ,_, manufacture_NN and_CC distribution_NN of_IN BHR_NNP products_NNS were_VBD acquired_VBN in_IN the_DT Warwick_NNP area_NN and_CC consolidated_JJ with_IN the_DT UK_NNP Orthopaedics_NNP operations_NNS ._.
The_DT expansion_NN in_IN the_DT Groups_NNS facilities_NNS did_VBD not_RB and_CC is_VBZ not_RB expected_VBN to_TO have_VB a_DT material_NN impact_NN on_IN liquidity_NN and_CC resources_NNS ._.
15_CD LEGAL_NNP PROCEEDINGS_NNS The_DT Company_NN and_CC its_PRP$ subsidiaries_NNS are_VBP parties_NNS to_TO product_NN liability_NN and_CC various_JJ legal_JJ proceedings_NNS ,_, some_DT of_IN which_WDT include_VBP claims_NNS for_IN substantial_JJ damages_NNS ,_, which_WDT are_VBP considered_VBN to_TO constitute_VB ordinary_JJ and_CC routine_JJ litigation_NN incidental_JJ to_TO the_DT businesses_NNS conducted_VBN by_IN the_DT Group_NNP ._.
The_DT outcome_NN of_IN such_JJ proceedings_NNS can_MD not_RB readily_RB be_VB foreseen_VBN ,_, but_CC other_JJ than_IN as_IN detailed_JJ below_IN management_NN believes_VBZ that_IN they_PRP will_MD not_RB result_VB in_IN any_DT material_NN adverse_JJ effect_NN onthe_NN of_IN operations_NNS of_IN the_DT Group_NNP ._.
In_IN August_NNP 2003_CD the_DT Group_NNP withdrew_VBD voluntarily_RB from_IN all_DT markets_NNS the_DT macrotextured_JJ versions_NNS of_IN its_PRP$ OXINIUM_NNP femoral_JJ knee_NN components_NNS ._.
As_IN at_IN that_DT date_NN 2,971_CD components_NNS had_VBD been_VBN implanted_VBN of_IN which_WDT approximately_RB 2,471_CD were_VBD in_IN the_DT USA_NNP ,_, 450_CD in_IN Australia_NNP and_CC 50_CD in_IN Europe_NNP ,_, the_DT first_JJ component_NN having_VBG been_VBN implanted_VBN in_IN December_NNP 2001_CD ._.
The_DT product_NN was_VBD withdrawn_VBN when_WRB management_NN became_VBD aware_JJ of_IN a_DT higher_JJR than_IN usual_JJ percentage_NN of_IN reports_NNS of_IN early_JJ revisions_NNS revisions_NNS are_VBP implants_NNS which_WDT need_VBP to_TO be_VB replaced_VBN ._.
It_PRP appears_VBZ that_IN some_DT patients_NNS do_VBP not_RB achieve_VB adequate_JJ initial_JJ fixation_NN and_CC that_IN in_IN other_JJ patients_NNS ,_, while_IN there_EX appears_VBZ to_TO be_VB good_JJ initial_JJ fixation_NN ,_, this_DT does_VBZ not_RB persevere_VB ._.
Smith_NNP &_CC Nephew_NNP has_VBZ extensively_RB tested_VBN and_CC investigated_VBN the_DT cause_NN of_IN these_DT early_JJ revisions_NNS ._.
A_DT group_NN of_IN medical_JJ and_CC scientific_JJ experts_NNS retained_VBN and_CC managed_VBN by_IN the_DT Groups_NNS defense_NN lawyers_NNS is_VBZ expected_VBN to_TO finish_VB its_PRP$ workinthis_NNS regard_VBP inmid-2006_NN ._.
As_IN at_IN 31_CD December_NNP 2005_CD 955_CD implants_NNS had_VBD been_VBN revised_VBN and_CC settlements_NNS agreed_VBD with_IN patients_NNS in_IN respect_NN of_IN 771_CD of_IN these_DT revisions_NNS ._.
The_DT total_JJ amount_NN paid_VBN out_RP in_IN settlements_NNS ,_, legal_JJ costs_NNS and_CC associated_VBN expenses_NNS was_VBD 78m_CD of_IN which_WDT 32m_NN was_VBD recovered_VBN from_IN the_DT insurer_NN that_WDT provides_VBZ the_DT primary_JJ layer_NN and_CC 65_CD %_NN of_IN the_DT first_JJ excess_JJ layer_NN in_IN the_DT Groups_NNS global_JJ product_NN liability_NN program_NN ._.
The_DT balance_NN of_IN 46m_CD is_VBZ due_JJ from_IN insurers_NNS in_IN respect_NN of_IN the_DT remainderof_JJ the_DT first_JJ excess_JJ layer_NN and_CC the_DT second_JJ excess_JJ layer_NN ._.
In_IN December_NNP 2004_CD the_DT Group_NNP was_VBD notified_VBN that_IN two_CD insurance_NN carriers_NNS who_WP comprise_VBP 35_CD %_NN of_IN the_DT first_JJ and_CC 80_CD %_NN of_IN the_DT second_JJ excess_JJ layers_NNS of_IN the_DT Groups_NNS global_JJ product_NN liability_NN program_NN had_VBD declined_VBN coverage_NN for_IN macrotextured_JJ claims_NNS due_JJ to_TO differences_NNS in_IN the_DT interpretation_NN of_IN the_DT policy_NN wording_NN ._.
In_IN December_NNP 2005_CD the_DT other_JJ insurance_NN carrier_NN with_IN a_DT 20_CD %_NN participation_NN in_IN the_DT second_JJ excess_JJ layer_NN declined_VBD coverage_NN ._.
Management_NNP intends_VBZ to_TO take_VB all_DT steps_NNS available_JJ to_TO it_PRP in_IN order_NN to_TO enforce_VB this_DT coverage_NN ._.
A_DT charge_NN of_IN 80m_CD representing_VBG the_DT amount_NN outstanding_JJ from_IN these_DT insurers_NNS and_CC an_DT estimate_NN of_IN the_DT cost_NN associated_VBN with_IN claims_NNS likely_JJ to_TO arise_VB in_IN the_DT future_JJ assuming_VBG that_DT insurance_NN cover_NN continues_VBZ to_TO be_VB unavailable_JJ from_IN these_DT and_CC subsequent_JJ excess_JJ layer_NN insurers_NNS was_VBD recorded_VBN in_IN 2004_CD ._.
Apart_RB from_IN the_DT impact_NN of_IN translational_JJ exchange_NN rate_NN movements_NNS there_RB has_VBZ been_VBN no_DT changeto_NN the_DT estimated_VBN liabilityduring2005_NNS ._.
The_DT charge_NN was_VBD calculated_VBN based_VBN on_IN :_: 1_LS the_DT amount_NN outstanding_JJ at_IN 31_CD December_NNP 2004_CD from_IN the_DT insurers_NNS who_WP declined_VBD coverage_NN :_: 2_CD an_DT estimate_NN of_IN the_DT average_JJ cost_NN in_IN respect_NN of_IN revisions_NNS where_WRB claims_NNS were_VBD unresolved_JJ at_IN that_DT date_NN :_: and_CC 3_CD an_DT estimate_NN of_IN the_DT number_NN of_IN settlements_NNS of_IN future_JJ revisions_NNS based_VBN on_IN the_DT current_JJ trend_NN and_CC decaying_VBG to_TO zero_CD after_IN five_CD years_NNS and_CC an_DT estimation_NN of_IN the_DT average_JJ future_JJ cost_NN per_IN settlement_NN ._.
The_DT amount_NN of_IN provision_NN remaining_VBG at_IN 31_CD December_NNP 2005_CD to_TO cover_VB pending_VBG claims_NNS and_CC claims_NNS in_IN respect_NN of_IN future_JJ revisions_NNS ,_, assuming_VBG noinsurancecoveris_NNS available_JJ ,_, was_VBD 44m_CD ,_, whichmanagement_NN believes_VBZ is_VBZ adequate_JJ ._.
As_IN at_IN 24_CD February_NNP 2006_CD ,_, 964_CD implants_NNS had_VBD been_VBN revised_VBN and_CC settlements_NNS agreed_VBD with_IN patients_NNS in_IN respect_NN of_IN 796_CD of_IN these_DT revisions_NNS ._.
The_DT Groups_NNS assessment_NN of_IN the_DT impact_NN of_IN these_DT revisions_NNS and_CC related_VBN matters_NNS constitute_VBP forward_RB looking_VBG statements_NNS that_WDT are_VBP subject_JJ to_TO uncertainties_NNS ,_, including_VBG uncertainties_NNS relating_VBG to_TO the_DT outcome_NN of_IN settlements_NNS as_IN compared_VBN to_TO the_DT assumptions_NNS made_VBN in_IN estimating_VBG claim_NN amounts_NNS ._.
Smith_NNP &_CC Nephew_NNP can_MD not_RB provide_VB assurance_NN that_IN these_DT estimates_NNS will_MD prove_VB correct_JJ ._.
Depending_VBG on_IN the_DT number_NN and_CC average_JJ cost_NN of_IN future_JJ settlements_NNS ,_, costs_NNS may_MD be_VB greater_JJR orless_JJ than_IN the_DT amountprovided_JJ see_VBP Risk_NNP Factors_NNP ._.
In_IN March_NNP 2005_CD the_DT US_NNP Attorneys_NNP Office_NNP in_IN Newark_NNP ,_, New_NNP Jersey_NNP issued_VBD a_DT subpoena_NN to_TO the_DT Groups_NNS orthopaedic_JJ business_NN asking_VBG for_IN copies_NNS of_IN its_PRP$ consulting_NN ,_, professional_JJ service_NN and_CC remuneration_NN agreements_NNS with_IN orthopaedic_JJ reconstructive_JJ surgeons_NNS ._.
Four_CD of_IN the_DT divisions_NNS major_JJ competitors_NNS received_VBD similar_JJ subpoenas_NNS ._.
The_DT Company_NN is_VBZ co-operating_JJ fully_RB with_IN the_DT US_NNP Attorney_NNP ,_, has_VBZ provided_VBN copies_NNS of_IN the_DT requested_VBN contracts_NNS and_CC is_VBZ gathering_VBG additional_JJ documentswhichhave_NN also_RB been_VBN requested_VBN ._.
